Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the...
Month: February 2025
Retrieve Medical Holdings Inc. Announces Letter of Intent to Acquire Cúratus LLC, Strengthening AI-Powered Healthcare Solutions
BEDMINSTER, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Retrieve Medical Holdings Inc. (“Retrieve”), a Nevada corporation, today announced that it...
Dror Successfully Completes User Experience Trial of its new ZSmile Platform
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), a pioneer in...
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing...
Entera Bio to Participate in Upcoming Events
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric CancersNEW...
Safety Shot CEO Jarrett Boon and Yerbaé CEO Todd Gibson Join FORCE Family Webinar to Discuss How Safety Shot Plans to Disrupt the Functional Wellness and Beverage Market
SCOTTSDALE, Ariz., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé”), a plant-based energy beverage...
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company...
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
VANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab,...
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for...
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide
Vivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea...
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Tobin “Toby” Schilke...
Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today...
FOXO TECHNOLOGIES, INC. ANNOUNCES EXECUTION OF A NON-BINDING ACQUISITION AGREEMENT FOR TWO ASSISTED-LIVING FACILITIES IN FLORIDA FOR A TOTAL CONSIDERATION OF $60 MILLION
MINNEAPOLIS, MN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company or FOXO”), announces that it has executed...
LifeMD® Announces Entry Into the Behavioral Health Market
Expansion to Include Teletherapy, Psychiatry and Medication Management Behavioral Health Offering to be Led by Industry Veteran Julian Cohen NEW...
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize...
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025...
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and...
Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced...
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in...